Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enzyvant Therapeutics, Inc.

http://www.enzyvant.com

Latest From Enzyvant Therapeutics, Inc.

What Pandemic Effect? US FDA’s 2021 Approval Class Is Off To Strong Start With 60+ Novel Candidates

Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.

Approvals Drug Review

Regenerative Medicine Comes Of Age – In The Age Of COVID-19

Regulatory review resource-intensive cell and gene therapy licensing applications are rolling toward US FDA along expedited pathways, while complete response letters and missed goal dates start to stack up under pandemic inspection constraints.

Regenerative Medicine Review Pathway

Mallinckrodt StrataGraft Skin Therapy Could Be The First RMAT-Designated Therapy Approved By US FDA

The company presented positive data from a Phase III pivotal trial during the American Burn Association virtual annual meeting.

Regenerative Medicine Clinical Trials

Dainippon Lays Out R&D Table Ahead Of Latuda Challenges

Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.

Clinical Trials Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Enzyvant Sciences, Ltd.
UsernamePublicRestriction

Register